Advantages of fast-acting ADP receptor blockade in ischemic heart disease.
Nurden
Alan T
AT
Nurden
Paquita
P
D000244:Adenosine Diphosphate / Q000378:metabolism / Q000502:physiology; D000249:Adenosine Monophosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000818:Animals; D004338:Drug Combinations; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy*; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000502:physiology; D013927:Thrombosis / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use
D004338:Drug Combinations; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; C117446:cangrelor; D010959:Tissue Plasminogen Activator